Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Rhea-AI Summary

Regulus Therapeutics (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA-targeted medicines, has announced its participation in two major healthcare investment conferences. The company will present at the Evercore 7th Annual HealthCONx Conference on December 3, 2024, at 3:50 p.m. ET, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 11:10 a.m. ET. Both presentations will be accessible through live events and replays on the company's investor relations website for 90 days after the events.

SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences:

• Evercore 7th Annual HealthCONx Conference: Fireside chat on Tuesday, December 3, 2024, at 3:50 p.m. ET
• Piper Sandler 36th Annual Healthcare Conference: Presentation on Wednesday, December 4, 2024, at 11:10 a.m. ET

The live events and replays of the presentations will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.

About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program and preclinical pipeline, the potential that RGLS8429 may be eligible for an Accelerated Approval pathway, potentially achieving therapeutic efficacy and clinical translation for patients, the expected timing for reporting interim or topline data, and the timing and future occurrence of other preclinical and clinical activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that the approach we are taking to discover and develop drugs is novel and may never lead to marketable products, that preliminary or topline results are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and may not be indicative of future results, the FDA has not designated RGLS8429 for an Accelerated Approval pathway and such designation may not lead to a faster development, regulatory review or approval process and does not increase the likelihood that RGLS8429 will receive marketing approval, the risk that preclinical and clinical studies may not be successful, risks related to regulatory review and approval, risks related to our reliance on third-party collaborators and other third parties, risks related to intellectual property, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, the risk that additional toxicology data may be negative, and risks related to our ability to successfully secure and deploy capital. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus' quarterly report on Form 10-Q available on the Company's website or at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-participation-at-upcoming-healthcare-investment-conferences-302315853.html

SOURCE Regulus Therapeutics Inc.

FAQ

When is Regulus Therapeutics (RGLS) presenting at the Evercore HealthCONx Conference 2024?

Regulus Therapeutics (RGLS) will present a fireside chat at the Evercore 7th Annual HealthCONx Conference on Tuesday, December 3, 2024, at 3:50 p.m. ET.

What time is RGLS presenting at the Piper Sandler Healthcare Conference 2024?

RGLS will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 11:10 a.m. ET.

How long will RGLS conference presentations be available for replay?

The presentations will be archived and available for replay on Regulus Therapeutics' investor relations website for 90 days following the presentation date.

Where can I watch Regulus Therapeutics (RGLS) conference presentations?

The presentations can be accessed through the 'Events and Presentations' section of Regulus Therapeutics' investor relations website at https://ir.regulusrx.com/events.